Evidence map›Paper›PMID 41312103›Full record

ArticleaBIOTECH2025

Targeted mutagenesis of

Lei Zhu, Shiyang Zhang, Qingfeng Niu, Yansha Li, Xiaomu Niu, Pengcheng Wang, Jian-Kang Zhu, Zhaobo Lang

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in aBIOTECH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lei Zhu *Institute of Advanced Biotechnology, Institute of Homeostatic Medicine, School of Medicine, Southern University of Science and Technology, Shenzhen, 518055 China.
Shiyang ZhangInstitute of Advanced Biotechnology, Institute of Homeostatic Medicine, School of Medicine, Southern University of Science and Technology, Shenzhen, 518055 China.
Qingfeng Niu *National Engineering Laboratory of Crop Stress Resistance Breeding, School of Life Sciences, Anhui Agricultural University, Hefei, 230036 China.
Yansha LiShandong Shunfeng Biotechnology Co. Ltd., Jinan, 250000 China.
Xiaomu NiuShandong Shunfeng Biotechnology Co. Ltd., Jinan, 250000 China.
Pengcheng WangInstitute of Advanced Biotechnology, Institute of Homeostatic Medicine, School of Medicine, Southern University of Science and Technology, Shenzhen, 518055 China.
Jian-Kang ZhuInstitute of Advanced Biotechnology, Institute of Homeostatic Medicine, School of Medicine, Southern University of Science and Technology, Shenzhen, 518055 China.
Zhaobo LangInstitute of Advanced Biotechnology, Institute of Homeostatic Medicine, School of Medicine, Southern University of Science and Technology, Shenzhen, 518055 China.ORCID 0000-0002-5551-0126

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GABA, a non-proteinogenic amino acid with anti-hypertensive properties, holds health-beneficial potential when enriched in crops. Previous studies have established that targeted disruption of the calmodulin-binding domain (CaMBD) of the tomato glutamate decarboxylase 3 (SlGAD3) enhances GABA biosynthesis. In this study, we used CRISPR/Cas9-mediated gene editing to precisely modify the CaMBD coding sequence of Supplementary Information: The online version contains supplementary material available at 10.1007/s42994-025-00249-w.

Indexed as

Gamma-aminobutyric acidGene editingGlutamate decarboxylaseTomato

Identifiers

PMID41312103
PMCPMC12647399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.